Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Life Science Investing
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors Life Science Investing
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group Life Science Investing
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis Life Science Investing
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences Technology Investing
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer Life Science Investing
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer Life Science Investing
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 Life Science Investing
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 Life Science Investing
The Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc. Life Science Investing
